Salem Investment Counselors’s CRISPR Therapeutics CRSP Stock Holding History

Salem Investment Counselors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.2K	Hold	535	–	–	﹤0.01%	709
2026 Q1	$25.4K	Buy	+535	New	+$28.2K	﹤0.01%	707
2025 Q4	–	Sell	-302	Closed	-$19.6K	–	556
2025 Q3	$19.6K	Hold	302	–	–	﹤0.01%	747
2025 Q2	$14.7K	Sell	302 -550	-65%	-$21.3K	﹤0.01%	784
2025 Q1	$29K	Hold	852	–	–	﹤0.01%	662
2024 Q4	$33.5K	Sell	852 -925	-52%	-$43.7K	﹤0.01%	647
2024 Q3	$83.5K	Buy	1,777 +2	+0.1%	+$101	﹤0.01%	480
2024 Q2	$95.9K	Hold	1,775	–	–	﹤0.01%	455
2024 Q1	$121K	Sell	1,775 -30	-2%	-$2.15K	﹤0.01%	427
2023 Q4	$113K	Hold	1,805	–	–	﹤0.01%	426
2023 Q3	$81.9K	Buy	1,805 +1,775	+5,917%	+$91.7K	﹤0.01%	450
2023 Q2	$1.69K	Buy	+30	New	+$1.7K	﹤0.01%	1018
2017 Q1	–	Sell	-650	Closed	-$13K	–	560
2016 Q4	$13K	Buy	+650	New	+$12.1K	﹤0.01%	476

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Salem Investment Counselors's CRSP Position: Q2 2026 in Review

Salem Investment Counselors held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 535 shares worth $29.2K. The position accounts for ﹤0.01% of the portfolio, ranked #709.

Salem Investment Counselors first reported a position in CRSP in Q4 2016 and has held it in 13 quarters since. The position peaked at $121K in Q1 2024. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Salem Investment Counselors held 535 shares of CRISPR Therapeutics worth $29.2K as of Q2 2026.
Salem Investment Counselors left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of Salem Investment Counselors's portfolio in Q2 2026, its #709 holding.
Salem Investment Counselors first reported a position in CRISPR Therapeutics in Q4 2016 and has held it in 13 quarters since.
Salem Investment Counselors's CRISPR Therapeutics position peaked at $121K in Q1 2024.
524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Salem Investment Counselors's 13F filing for Q2 2026, filed 14 Jul 2026.